The short answer. The DAMO Hair Loss Solution franchise is not a salon and not a hair transplant clinic. It is a non-surgical, clinical hair and scalp restoration brand out of New York, and for the first time in its history it is releasing a master license — with exclusive territory rights available across Asia Pacific and MENA. The published investment level is US$500,000, most commercial terms are disclosed under NDA, and the realistic timeline from signature to an operating clinic is nine to twelve months. For an investor, the question is not whether hair loss demand exists — it plainly does — but whether you can staff a clinical operation and build a category-defining position before someone else takes the territory.
DAMO is a clinical hair and scalp restoration brand founded in New York by Dr. June Noh, a Doctor of Traditional Chinese Medicine and Certified Clinical Trichologist with more than 16 years of clinical practice. The business sits deliberately between two categories that most consumers find unsatisfying: cosmetic salon treatments that do not address the underlying condition, and surgical transplants that are expensive, invasive and not appropriate for most sufferers.
What has been built instead is a documented clinical protocol — the DAMO Response-Based Hair Recovery System — delivered by a multidisciplinary team spanning traditional Chinese medicine, nursing, trichology and nutrition. The brand reports 2,000+ cases treated across 30+ nationalities and operates six locations across the United States, with clinics spanning New York, New Jersey and California. That multi-site footprint matters more than it might appear: it is the evidence that the model runs without the founder standing in the room.
The protocol runs in four stages, which is what makes it transferable to a licensee:
Revenue arrives in layers rather than from a single transaction: in-clinic treatment programmes, a retail home-care product line, and — under a master license — the right to sub-license practitioners and locations within your territory.
This is the part that distinguishes the opportunity from a standard unit franchise. DAMO is releasing its first-ever master license, which grants exclusive territory rights plus the right to sub-license practitioners and locations inside that market. A master partner is therefore not buying one clinic. They are buying the position of brand owner-operator for a country, with the ability to build both company-operated clinics and a sub-licensed network.
For anyone unfamiliar with how these structures work in practice, our guide to country-level franchise rights across Asia Pacific and MENA covers the mechanics of territory definition, development schedules and sub-licensing economics.
| Item | Position |
|---|---|
| Headquarters | New York, USA |
| Industry | Health & Wellness — hair and scalp restoration |
| Investment level | US$500,000 |
| Territory fee | Disclosed under NDA |
| Unit fee | Disclosed under NDA |
| Royalty | Disclosed under NDA |
| Term | Disclosed under NDA |
| Time to first clinic | Approximately 9–12 months |
| Markets available | Selected territories across Asia Pacific and MENA |
Full unit economics and commercial terms are released to qualified partners during the review process. Figures above reflect the brand’s published position as represented by VF Franchise Consulting.
Hair loss is one of the few consumer health categories where demand is close to universal, non-discretionary in emotional terms, and recurring by clinical necessity. Androgenetic alopecia — pattern hair loss — is the most common form, and according to NIH-published clinical literature, it affects more than half of older men and roughly 15% of postmenopausal women. DAMO’s own materials put the global affected population above two billion people.
Three characteristics make it commercially attractive relative to most wellness formats:
That last point is the real argument. This is not a category where a master partner is fighting for share against ten established chains. In most target markets there is no incumbent brand at all.
Selected territories remain available across ASEAN, North Asia, China, India and Australasia, alongside MENA. The fit is strongest where three conditions overlap: high consumer awareness of US- and Korean-origin wellness brands, established medical-aesthetic spending, and a regulatory environment that permits non-surgical clinical treatment under qualified staff.
On that basis, the Gulf is an obvious early candidate — the same premium-wellness demand documented in our analysis of boutique wellness growth across the GCC and in the Saudi Arabian franchise market. In Southeast Asia, Singapore and Vietnam both combine strong medical-aesthetic markets with receptive consumers.
DAMO does not require the master partner to be a clinician. It does require access to qualified clinical or nursing staff, because the protocol is delivered by licensed practitioners. The brand supplies protocols, training and certification.
The profile that works:
It is a poor fit for purely passive capital, for investors without a route to clinical staffing, or for anyone expecting retail-speed payback.
The published investment level is US$500,000. Territory fee, unit fee, royalty, marketing contribution and term are disclosed under NDA and vary by market and format, with full unit economics shared with qualified partners during the review process.
Exclusive rights to a defined territory, plus the right to sub-license practitioners and locations within that market — allowing a partner to build company-operated clinics, a sub-licensed network, or both.
No. You need access to qualified clinical or nursing staff. DAMO provides the protocols, training and certification, and the system is designed to be delivered by a licensed multidisciplinary team.
Approximately nine to twelve months, covering discovery and training through to clinic build-out and launch.
Selected markets across Asia Pacific and MENA, including ASEAN, North Asia, China, India and Australasia. Because this is a first-release master license, availability is changing as territories are awarded.
What makes DAMO unusual is not the treatment category but the timing. Most brands that reach Asia Pacific and MENA arrive after their home market is saturated and after the best regional territories have been carved up. DAMO is releasing country rights for the first time, in a category where almost no market in the region has an organised branded competitor. That combination — proven clinical protocol, multi-site US validation, and genuinely open territory — does not appear often, and by definition does not last.
Full brand details are published on the DAMO® Hair Loss Solution brand page, and the brand is among those meeting investors at our private master franchise sessions in Singapore on 13–14 August 2026. The brand’s consumer site is damohairlosssolution.com.
Written by Sean T. Ngo, CEO and Co-founder of VF Franchise Consulting. DAMO® Hair Loss Solution is represented by VF Franchise Consulting, with full-time in-market directors across Vietnam, Singapore, Korea and Japan.
Email: info@vffranchiseconsulting.com | Hotline: +84 90 306 54 58
